We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Effectiveness of Sculptra Aesthetic for Correction of Cheek Wrinkles

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04124692
Recruitment Status : Completed
First Posted : October 11, 2019
Last Update Posted : August 26, 2022
Sponsor:
Information provided by (Responsible Party):
Galderma R&D

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The study has been designed to evaluate the safety and effectiveness of Sculptra Aesthetic as a single regimen for correction of cheek wrinkles after changes in reconstitution and injection procedures compared to the approved label.

Condition or disease Intervention/treatment Phase
Cheek Wrinkles Device: Sculptra Aesthetic new dilution Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 149 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Evaluator-blinded, No-treatment Controlled, Multicenter Study to Evaluate the Effectiveness and Safety of Sculptra Aesthetic for Correction of Cheek Wrinkles.
Actual Study Start Date : November 12, 2019
Actual Primary Completion Date : August 12, 2021
Actual Study Completion Date : August 12, 2021
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
No Intervention: No-treatment control group
Experimental: Treatment group Device: Sculptra Aesthetic new dilution
Treatment of cheek wrinkles


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Responder rate for a single regimen of Sculptra Aesthetic versus a no-treatment control in the correction of cheek wrinkles. [ Time Frame: Month 9 ]
    A responder is defined as a participant with at least 1 grade improvement from baseline on both sides of the face concurrently, on the Galderma Cheek Wrinkles Scale (GCWS) ranging from 0 (none) to 4 (very severe).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Intent to undergo correction of cheek wrinkles on both sides of the face and a Galderma Cheek Wrinkles Scale (GCWS) At Rest score of Moderate or Severe on EACH side of the face.

Exclusion Criteria:

  • Known/previous allergy or hypersensitivity to any of the Sculptra Aesthetic constituents.

  • Previous tissue augmenting therapy, contouring or revitalization treatment in the face, except the lips, with any of the following fillers prior to Baseline visit:

    1. Collagen, Hyaluronic Acid - 12 months
    2. Calcium Hydroxyapatite (CaHa), Poly L- Lactic Acid (PLLA) or permanent (nonbiodegradable)- Prohibited
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04124692


Locations
Layout table for location information
United States, Arizona
Galderma Research Site
Scottsdale, Arizona, United States, 85255
United States, California
Galderma Research Site
Encino, California, United States, 91436
Galderma Research Site
Redondo Beach, California, United States, 90277
Galderma Research Site
San Diego, California, United States, 92121
United States, District of Columbia
Galderma Research Site
Washington, District of Columbia, United States, 20037
United States, Florida
Galderma Research Site
Coral Gables, Florida, United States, 33143
United States, Georgia
Galderma Research Site
Alpharetta, Georgia, United States, 30022
United States, Louisiana
Galderma Research Site
New Orleans, Louisiana, United States, 70115
United States, Maryland
Galderma Research Site
Rockville, Maryland, United States, 20852
United States, New York
Galderma Research Site
New York, New York, United States, 10021
Galderma Research Site
New York, New York, United States, 10028
United States, Texas
Galderma Research Site
Dallas, Texas, United States, 75254
Galderma Research Site
Spring, Texas, United States, 77388
Sponsors and Collaborators
Galderma R&D
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Galderma R&D
ClinicalTrials.gov Identifier: NCT04124692    
Other Study ID Numbers: 43USSA1812
First Posted: October 11, 2019    Key Record Dates
Last Update Posted: August 26, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes